329 related articles for article (PubMed ID: 25561335)
1. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
Mendes RE; Sader HS; Flamm RK; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2015 Mar; 59(3):1811-4. PubMed ID: 25561335
[TBL] [Abstract][Full Text] [Related]
2. Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014).
Mendes RE; Sader HS; Smart JI; Castanheira M; Flamm RK
Eur J Clin Microbiol Infect Dis; 2017 Jun; 36(6):1013-1017. PubMed ID: 28111724
[TBL] [Abstract][Full Text] [Related]
3. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
4. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
Duncan LR; Smith CJ; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
[TBL] [Abstract][Full Text] [Related]
5. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Mendes RE; Moet GJ; Janechek MJ; Jones RN
Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
McMullen AR; Lainhart W; Wallace MA; Shupe A; Burnham CD
Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
[TBL] [Abstract][Full Text] [Related]
8. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2015 Jan; 59(1):702-6. PubMed ID: 25348529
[TBL] [Abstract][Full Text] [Related]
9. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
Marconescu P; Graviss EA; Musher DM
Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
[TBL] [Abstract][Full Text] [Related]
10. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
[TBL] [Abstract][Full Text] [Related]
11. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
[TBL] [Abstract][Full Text] [Related]
13. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Karlowsky JA; Nichol K; Zhanel GG
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
[TBL] [Abstract][Full Text] [Related]
14. Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.
Pfaller MA; Rhomberg PR; Huband MD; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993854
[TBL] [Abstract][Full Text] [Related]
15. A correlation between reduced susceptibilities to vancomycin and daptomycin among the MRSA isolates selected in mutant selection window of both vancomycin and daptomycin.
Fujimura S; Nakano Y; Watanabe A
J Infect Chemother; 2014 Dec; 20(12):752-6. PubMed ID: 25287155
[TBL] [Abstract][Full Text] [Related]
16. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
Saravolatz LD; Pawlak J; Johnson LB
J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
[TBL] [Abstract][Full Text] [Related]
17. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
Rose WE; Fallon M; Moran JJ; Vanderloo JP
Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
[TBL] [Abstract][Full Text] [Related]
19. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
20. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
Mendes RE; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
